Stem Cell Strategies to Evaluate Idiosyncratic Drug-induced Liver Injury

被引:7
|
作者
Krueger, Winfried [1 ]
Boelsterli, Urs A. [1 ]
Rasmussen, Theodore P. [1 ,2 ,3 ]
机构
[1] Univ Connecticut, Dept Pharmaceut Sci, 69 North Eagleville Rd,U-3092, Storrs, CT 06269 USA
[2] Univ Connecticut, Dept Mol & Cell Biol, Storrs, CT USA
[3] Univ Connecticut, Stem Cell Inst, Storrs, CT USA
关键词
DILI; Embryonic stem cell; iPS; Toxicity; Genetics;
D O I
10.14218/JCTH.2014.00012
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The host-dependent nature of idiosyncratic drug-induced liver injury (iDILI) suggests that rare genetic polymorphisms may contribute to the disease. Indeed, a few mutations in key genes have already been identified using conventional human genetics approaches. Over 50 commonly used drugs can precipitate iDILI, making this a substantial medical problem. Only recently have human induced pluripotent stem cells been used as a research tool to discover novel iDILI genes and to study the mechanisms of iDILI in vitro. Here we review the current state of stem cell use in the investigation of iDILI, with a special focus on genetics. In addition, the concerns and difficulties associated with genetics and animal model research are discussed. We then present the features of patient-specific pluripotent stem cells (which may be derived from iDILI patients themselves), and explain why these cells may be of great utility. A variety of recent approaches to produce hepatocyte-like cells from pluripotent cells and the associated advantages and limitations of such cells are discussed. Future directions for the use of stem cell science to investigate iDILI include novel ways to identify new iDILI genes, a consideration of epigenetic impacts on iDILI, and the development of new and improved strategies for the production of hepatocytes from human pluripotent cells. (C) 2014 The Second Affiliated Hospital of Chongqing Medical University. Published by XIA & HE Publishing Ltd. All rights reserved.
引用
收藏
页码:143 / 152
页数:10
相关论文
共 50 条
  • [1] Idiosyncratic drug-induced liver injury: an overview
    Hussaini, S. Hyder
    Farrington, Elizabeth A.
    EXPERT OPINION ON DRUG SAFETY, 2007, 6 (06) : 673 - 684
  • [2] Models of Idiosyncratic Drug-Induced Liver Injury
    Yokoi, Tsuyoshi
    Oda, Shingo
    ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 61, 2021, 2021, 61 : 247 - 268
  • [3] Epidemiology of Idiosyncratic Drug-Induced Liver Injury
    Bell, Lauren N.
    Chalasani, Naga
    SEMINARS IN LIVER DISEASE, 2009, 29 (04) : 337 - 347
  • [4] The diagnosis and management of idiosyncratic drug-induced liver injury
    Hassan, Ammar
    Fontana, Robert J.
    LIVER INTERNATIONAL, 2019, 39 (01) : 31 - 41
  • [5] Idiosyncratic drug-induced liver injury: A clinical update
    Maddur H.
    Chalasani N.
    Current Gastroenterology Reports, 2011, 13 (1) : 65 - 71
  • [6] Risk Factors for Idiosyncratic Drug-Induced Liver Injury
    Chalasani, Naga
    Bjornsson, Einar
    GASTROENTEROLOGY, 2010, 138 (07) : 2246 - 2259
  • [7] Idiosyncratic Drug-Induced Liver Injury: A Short Review
    Yamashita, Yo-ichi
    Imai, Katsunori
    Mima, Kosuke
    Nakagawa, Shigeki
    Hashimoto, Daisuke
    Chikamoto, Akira
    Baba, Hideo
    HEPATOLOGY COMMUNICATIONS, 2017, 1 (06) : 494 - 500
  • [8] The Evolving Profile of Idiosyncratic Drug-Induced Liver Injury
    Fontana, Robert J.
    Bjornsson, Einar S.
    Reddy, Rajender
    Andrade, Raul J.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (08) : 2088 - 2099
  • [9] Uncommon Presentations of Idiosyncratic Drug-Induced Liver Injury
    Raj Vuppalanchi
    Marwan Ghabril
    Current Hepatology Reports, 2018, 17 (3) : 254 - 259